Mytos, a London-based automated cell manufacturing company, recently announced that it has raised $19M in Series A funding. The funding round was led by Buckley Ventures, with participation from IQ Capital and Wing VC. The primary purpose of this funding is to accelerate the manufacturing and distribution of Mytos' automated cell production system to meet the growing demand among biotech and pharma companies.
Mytos, led by Ali Afshar, Ph.
.D, CEO, and Ignacio Willats, specializes in automating cell manufacture. Their platform offers life sciences companies the capability to grow human cells with precision and efficiency. With a team of talented engineers and scientists, Mytos has developed an automated platform that enables the accelerated development of life-saving therapies. The platform starts with stem cells and efficiently manufactures heart cells that begin beating after just 12 days. By automating the entire cell manufacturing process, Mytos not only ensures high cell production and yield but also allows remote monitoring of cell quality through accessible digital data capture on smartphones or other digital devices.
Already, a number of life sciences companies across the globe are benefitting from Mytos' platform. With the recently secured funding, Mytos plans to expand its manufacturing capabilities, making its automated cell production system accessible to even more biotech and pharma companies worldwide. The growing demand for advanced cell manufacturing solutions in the life sciences industry makes Mytos a company to watch as it continues to revolutionize and streamline the cell production process.